November 18, 2021 10:50 AM EST

J&J uncorks long-term data for Crohn's disease candidate; Age-related disease biotech earns Eli Lilly's backing

Max Gelman

Senior Editor

Paul Schloesser

Associate Editor

J&J and AbbVie are competing for the same Crohn’s disease market with their respective IL-23 drugs, Tremfya and Skyrizi. On Wednesday, J&J’s Janssen unit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J uncorks long-term data for Crohn's disease candidate; Age-related disease biotech earns Eli Lilly's backing

Max Gelman

Senior Editor

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Exclusive: Florida cancer biotech raises $100M Series A

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

J&J un­corks long-term da­ta for Crohn's dis­ease can­di­date; Age-re­lat­ed dis­ease biotech earns Eli Lil­ly's back­ing

Senior Editor

Associate Editor

Sign up to read this article for free.

more like this

J&J uncorks long-term data for Crohn's disease candidate; Age-related disease biotech earns Eli Lilly's backing